Endo refinances secured debt in 2017 for more operating flexibility

By Devika Patel

Knoxville, Tenn., Feb. 27 – Endo International plc said it refinanced its secured debt in 2017 in order to gain more operating flexibility.

“In 2017, we successfully refinanced our secured debt to provide the company with additional operating flexibility,” executive vice president and chief financial officer Blaise Coleman said on the company’s fourth-quarter and year ended Dec. 31, 2017 earnings conference call on Tuesday.

Fourth-quarter 2017 adjusted EBITDA was $327 million, compared to fourth-quarter 2016 adjusted EBITDA of $556 million. Full-year 2017 adjusted EBITDA was $1,568,000,000.

As of Dec. 31, 2017, the company had $987 million in unrestricted cash; $8.3 billion of debt; approximately $7.3 billion of net debt and a net debt to adjusted EBITDA ratio of 4.6x.

Endo is a Dublin, Ireland-based specialty pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.